Cargando…

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models

Objective: Diabetic kidney disease (DKD) is one of the most prevalent complications of diabetes mellitus (DM) and is highly associated with devastating outcomes. Hypoxia-inducible factor (HIF), the main transcription factor that regulates cellular responses to hypoxia, plays an important role in reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yumin, Cui, Wen, Zhang, Yiding, Wang, Ting, Zheng, Xuejun, Li, Huangmin, Shang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465800/ https://www.ncbi.nlm.nih.gov/pubmed/37654676 http://dx.doi.org/10.3389/fphys.2023.1195441

Ejemplares similares

Radioprotective effects of roxadustat (FG‐4592) in haematopoietic system
por: Zhang, Pei, et al.
Publicado: (2018)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice
por: Wang, Peipei, et al.
Publicado: (2022)

Osteoblast–Osteoclast Coculture Amplifies Inhibitory Effects of FG‐4592 on Human Osteoclastogenesis and Reduces Bone Resorption
por: Hulley, Philippa A, et al.
Publicado: (2020)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
por: Feng, Zhenlan, et al.
Publicado: (2022)

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways
por: Long, Guangfeng, et al.
Publicado: (2020)

Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid
por: Li, Xue, et al.
Publicado: (2022)

Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
por: Li, Axiang, et al.
Publicado: (2023)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
por: Li, Xuan, et al.
Publicado: (2018)

The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model
por: Zhou, Muran, et al.
Publicado: (2019)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway
por: Li, Xue, et al.
Publicado: (2020)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
por: Miao, A-Feng, et al.
Publicado: (2021)

Diagnostic value of α1-MG and URBP in early diabetic renal impairment
por: Zhou, Yukun, et al.
Publicado: (2023)

Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action
por: Chang, Wei-Ting, et al.
Publicado: (2019)

Combination of the gut microbiota and clinical indicators as a potential index for differentiating idiopathic membranous nephropathy and minimal change disease
por: Jiang, Yumin, et al.
Publicado: (2023)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells
por: Fujimaki, Ayaka, et al.
Publicado: (2023)

The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease
por: Wu, Xiaofang, et al.
Publicado: (2023)

Gut microbiota, key to unlocking the door of diabetic kidney disease
por: Wang, Peipei, et al.
Publicado: (2021)

Characterization and diagnostic value of the gut microbial composition in patients with minimal change disease
por: Zhang, Yiding, et al.
Publicado: (2022)

Mouse Microbiota Models: Comparing Germ-Free Mice and Antibiotics Treatment as Tools for Modifying Gut Bacteria
por: Kennedy, Elizabeth A., et al.
Publicado: (2018)

Pb Toxicity on Gut Physiology and Microbiota
por: Liu, Wenya, et al.
Publicado: (2021)

The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
por: Bliss, Edward S., et al.
Publicado: (2018)

Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis
por: Luo, Mei, et al.
Publicado: (2017)

Barrier properties of Nup98 FG phases ruled by FG motif identity and inter-FG spacer length
por: Ng, Sheung Chun, et al.
Publicado: (2023)

Commensal Homeostasis of Gut Microbiota-Host for the Impact of Obesity
por: Zhang, Pengyi, et al.
Publicado: (2018)

The Crosstalk between the Gut Microbiota and Mitochondria during Exercise
por: Clark, Allison, et al.
Publicado: (2017)

Selective Regional Alteration of the Gut Microbiota by Diet and Antibiotics
por: Poteres, Elesa, et al.
Publicado: (2020)

Gut Microbiota and Chemical-Induced Acute Liver Injury
por: Chen, Tao, et al.
Publicado: (2021)

Effect of Cigarette Smoke on Gut Microbiota: State of Knowledge
por: Gui, Xiaohua, et al.
Publicado: (2021)

Gut microbiota dependant trimethylamine N-oxide and hypertension
por: Mutengo, Katongo H., et al.
Publicado: (2023)

Efficacy of Probiotic Compounds in Relieving Constipation and Their Colonization in Gut Microbiota
por: He, Yuan, et al.
Publicado: (2022)

Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome
por: Wollny, Tomasz, et al.
Publicado: (2021)

Obesity-Driven Gut Microbiota Inflammatory Pathways to Metabolic Syndrome
por: Cavalcante-Silva, Luiz H. A., et al.
Publicado: (2015)

Links between Dietary Protein Sources, the Gut Microbiota, and Obesity
por: Madsen, Lise, et al.
Publicado: (2017)

The Effects of Weaning Methods on Gut Microbiota Composition and Horse Physiology
por: Mach, Núria, et al.
Publicado: (2017)

Pathogenesis of Children’s Allergic Diseases: Refocusing the Role of the Gut Microbiota
por: Hu, Tingting, et al.
Publicado: (2021)

Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease
por: Sultan, Salma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dtg7cjdj9bvth904754ttghgjr